Prokarium Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$7.93M
- Investors
-
11
Prokarium General Information
Description
Operator of a biopharmaceutical company intended for developing bacterial immunotherapies for cancer. The company's proprietary technology naturally homes to tumors, stimulates anti-tumor immune responses, and can be programmed to deliver therapeutic agents directly inside the tumor microenvironment, targeting non-muscle invasive bladder cancer, enabling the healthcare industry to treat patients with cancers whose tumors resist or do not respond well to current immunotherapies.
Contact Information
Website
www.prokarium.comCorporate Office
- London Bioscience Innovation Centre
- 2 Royal College Street
- London NW1 0NH
- England, United Kingdom
Corporate Office
- London Bioscience Innovation Centre
- 2 Royal College Street
- London NW1 0NH
- England, United Kingdom
Prokarium Timeline
Prokarium Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 02-Dec-2025 | $7.93M | Completed | Clinical Trials - Phase 1 | ||
| 9. Accelerator/Incubator | 01-Jan-2024 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC (Series B2) | 09-Feb-2023 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC (Series B) | 27-Oct-2020 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 08-Oct-2019 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series A) | 26-Feb-2018 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 25-Jul-2016 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 03-Aug-2015 | Completed | Clinical Trials - Phase 1 | |||
| 2. Grant | 11-Mar-2013 | $609K | $12.5M | Completed | Startup | |
| 1. Seed Round | 01-Jan-2012 | $12.5M | $12.5M | Completed | Startup |
Prokarium Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 169,305 | $0.013147 | $34.22 | $34.22 | 1x | $34.22 | 3.26% | |
| Ordinary | 670,000 | $0.013147 | $36.53 | $36.53 | 1x | $36.53 | 12.91% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Prokarium Comparisons
Industry
Financing
Details
Prokarium Competitors (29)
One of Prokarium’s 29 competitors is Actym Therapeutics, a Venture Capital-Backed company based in Berkeley, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Actym Therapeutics | Venture Capital-Backed | Berkeley, CA | ||||
| T3 Pharmaceuticals | Formerly VC-backed | Allschwil, Switzerland | ||||
| Redbiotec | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Genocea Biosciences | Formerly VC-backed | Cambridge, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
Prokarium Patents
Prokarium Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202502951-D0 | Nucleic acid construct | Pending | 28-Feb-2025 | ||
| WO-2026180692-A1 | Nucleic acid construct | Pending | 28-Feb-2025 | ||
| GB-202502950-D0 | Quorum sensing | Pending | 28-Feb-2025 | ||
| WO-2026180700-A1 | Quorum sensing circuit | Pending | 28-Feb-2025 | ||
| GB-202411952-D0 | Flagellar secretion systems | Inactive | 14-Aug-2024 |
Prokarium Signals
Prokarium Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Grow London | Accelerator/Incubator | |||
| Ginkgo Bioworks | VC-Backed Company | Minority | ||
| British Business Bank | Lender/Debt Provider | Minority | ||
| Wellcome Trust | Limited Partner | Minority | ||
| Korea Investment Partners | Venture Capital | Minority |
Prokarium FAQs
-
When was Prokarium founded?
Prokarium was founded in 2012.
-
Where is Prokarium headquartered?
Prokarium is headquartered in London, United Kingdom.
-
What is the size of Prokarium?
Prokarium has 18 total employees.
-
What industry is Prokarium in?
Prokarium’s primary industry is Drug Discovery.
-
Is Prokarium a private or public company?
Prokarium is a Private company.
-
What is the current valuation of Prokarium?
The current valuation of Prokarium is .
-
What is Prokarium’s current revenue?
The current revenue for Prokarium is .
-
How much funding has Prokarium raised over time?
Prokarium has raised $90.4M.
-
Who are Prokarium’s investors?
Grow London, Ginkgo Bioworks, British Business Bank, Wellcome Trust, and Korea Investment Partners are 5 of 11 investors who have invested in Prokarium.
-
Who are Prokarium’s competitors?
Actym Therapeutics, T3 Pharmaceuticals, Redbiotec, Genocea Biosciences, and Adaptimmune Therapeutics are some of the 29 competitors of Prokarium.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process